Table 4. Non-inferiority analysis results of SBA responders per serogroup and analyses.

	Total population		Non-immune population
Serogroup A	MITT (n = 743)		(n = 361)
	Diff.	95%CI	Diff.	95%CI
Full dose vs 1/5	+8.9%	[+2.1%, +15.7%]	+2.4%	[−3.9%, +8.8%]
Full dose vs 1/10	+17.0%	[+9.8%, +24.2%]	+6.3%	[−0.7%, +13.3%]
Serogroup W135	MITT (n = 744)		(n = 576)
	Diff.	95%CI	Diff.	95%CI
Full dose vs 1/5	−1.6%	[−5.7%, +2.6%]	−0.7%	[−5.4%, +3.9%]
Full dose vs 1/10	−2.2%	[−6.2%, +1.9%]	−3.5%	[−7.5%, +0.5%]
Serogroup C	MITT (n = 729)		(n = 684)
	Diff.	95%CI	Diff.	95%CI
Full dose vs 1/5	+10.6%	[+4.4%;+16.7%]	+11.5%	[+5.4%;+17.5%]
Full dose vs 1/10	+14.5%	[+8.1%;+21.0%]	+15.8%	[+9.2% ; +22.3%]
Serogroup Y	MITT (n = 741)		(n = 724)
	Diff.	95%CI	Diff.	95%CI
Full dose vs 1/5	+2.0%	[−4.5%;+8.5%]	+2.6%	[−4.1%;+9.3%]
Full dose vs 1/10	+0.6%	[−5.7%;+6.9%]	+0.6%	[−5.8%;+7.0%]